BlackRock Health Sciences Trust (BME)
NYSE NYSE Primary 
XFRA 
BME And FLC: There Are Still Pockets Of Opportunities
Closed-end funds have seen significant discount narrowing in 2024 across the board, as discounts have been cut in more than half on average. Despite record highs being hit regularly this year in the S&P 500, NASDAQ 100, and DJIA, opportunities still exist as not everything has been participating on the upside equally. Investors could consider funds like the BME and FLC, which may still offer attractive entry points despite the overall discount narrowing in the CEF space and elevated broader equity markets.
My Top Retirement Strategy For 14% Dividends In 2025
Not many people know this, but if you really want to diversify—deftly balancing and rebalancing to maximize (and protect) your gains, you need to invest in closed-end funds (CEFs).
BME: 8.4% Yield From An Undervalued Sector
Last time around, we had rated BlackRock Health Sciences Trust as a hold. The fund has not delivered much since then, but the sector has gotten really oversold. We go over the thesis for this one today and tell you why we think its is a Buy.
B&M jumps as spending pressures help drive discounter's sales
B&M European Value Retail SA (LSE:BME) shares gained ground on Thursday after the discounter posted improved first-half figures as cost pressures continued to drive demand. Group sales climbed by 3.7% to £2.64 billion over the six months to September, aided by a 6.0% uptick across the UK in the second quarter, B&M reported on Thursday.
BME: Defensive Healthcare Exposure With A Tender Offer Opportunity
BlackRock Health Sciences Trust offers exposure to healthcare companies and employs a covered call strategy to generate option premiums to help support the distribution. The latest tender offer measurement period for BlackRock discount management programs has come to a close, and BME made the list, but it was close this time. The fund's 6.15% distribution yield might not be the most exciting, but it is one of the most consistent and steady you'll find in the CEF space.
BME: Discount To NAV But High Fees And Volatility
BME has delivered solid long-term returns since its 2005 launch, earning positive ratings from Seeking Alpha analysts, with most recent articles rating it a Buy or Strong Buy. The trust has a relatively high expense ratio and has experienced significant volatility related to trading levels relative to NAV. BlackRock recently announced a tender offer that will allow 2.5% of the fund's units to be repurchased at 98% of NAV.
BME: An Attractive Discount On This Healthcare CEF
BlackRock Health Sciences Trust (BME) offers exposure to the healthcare space while also utilizing a covered call strategy. BME's discount has narrowed since our last update but remains attractive, with the potential for attractive returns going forward. BME's distribution yield may be more modest than other CEFs, but that has helped it boast of never having to cut the regular distribution and helped it provide some capital.
BME: Future Interest Rate Cuts May Be A Catalyst
BlackRock Health Sciences Trust trades at an attractive discount to net asset value. The dividend yield of 6.1% remains supported from net investment income. Some weakness revolves around the use of return of capital, however. Future interest rate cuts may serve as a price catalyst. Inflation continues to cool while the unemployment rate ticks upward.
B&M launches store openings as sales edge higher
B&M European Value Retail SA (LSE:BME), the discount retailer, saw its sales edge higher in the first quarter helped by new store openings and volume growth. Group sales increased by 2.4%, reaching £1,345 million for the 13-week period ending 29 June 2024.
BME: Quality Healthcare Fund With 6% Income And An Attractive Discount
BlackRock Health Sciences Trust is a healthcare sector-specific closed-end fund that invests in a fairly diversified portfolio of common stocks in the healthcare sector. It currently provides a reasonable yield of 6.3% plus an attractive discount of close to -8% (below NAV). The BME closed-end fund has a very decent long-term record of nearly 19 years, matching and even exceeding the performance of the S&P 500. However, the recent near and midterm performance has been lackluster.
B&M shares tumble on ‘curious' omission of guidance in results
B&M European Value Retail SA (LSE:BME) shares have tumbled more than 6% after it posted what analysts said was a “curious” set of full-year results. During the twelve months, underlying earnings came in at the top end of guidance, on the back of new store openings and what management said was volume-led growth.
B&M sees new store openings drive profit surge
B&M European Value Retail SA (LSE:BME), the discount retailer, saw its profits hit the top end of guidance for the year as it expanded its store footprint and demand spiked. Full-year underlying earnings reached £629 million, compared to guidance of between £620 million and £630 million, marking a 9.7% jump year-on-year.
